Drug company giant, GSK, have been fined £37.6 million for market abuse in striking deals to delay the launch of cheap generic copies of its former blockbuster antidepressant Seroxat®.

A number of generic companies who were involved were also fined smaller amounts, including Germany’s Merck. Read the full story in the Irish Independent.